

## Supplementary Online Content

Dobson SRM, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of human papillomavirus vaccine in younger adolescents versus 3 doses in young women. *JAMA*. doi:10.1001/jama.2013.1625

**eTable 1.** Baseline Characteristics of Study Participants at Enrollment by Groups and by Centers

**eTable 2.** Summary of month 7 anti HPV cLIA geometric mean titres in milli Merck Unit per mL (mMU/mL) of the imputed ITT population of two-dose and three-dose vaccine recipients

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Baseline Characteristics of Study Participants at Enrollment by Groups and by Centers

	British Columbia	Nova Scotia	Quebec	Total
<b>Group 1</b>	<b>65</b>	<b>107</b>	<b>87</b>	<b>259</b>
Age, mean (SD), yrs	12.0 (1.3)	12.9 (1.2)	11.9 (1.4)	12.3 (1.4)
Weight, mean (SD), kg	45.8 (9.9)	49.6 (10.8)	44.3 (10.7)	46.8 (10.8)
BMI	19.3 (2.8)	20.4 (3.7)	18.9 (3.6)	19.6 (3.5)
Ethnicity, n (%)				
White	56 (86.2)	101 (94.4)	85 (97.7)	242 (93.4)
Other	9 (13.8)	6 (5.6)	2 (2.3)	17 (6.6)
Sexual History				
Postmenarchal, n (%)	23 (35.4)	60 (56.1)	33 (37.9)	116 (44.8)
Sexually active, n (%)	0	0	0	0
Baseline HPV Results Seropositivity, n (%)				
HPV-16	0	0	0	0
HPV-18	0	0	0	0
HPV-6	0	0	2 (2.3)	2 (0.8)
HPV-11	0	0	0	0
<b>Group 2</b>	<b>64</b>	<b>110</b>	<b>87</b>	<b>261</b>
Age, mean (SD), yrs	12.0 (1.3)	12.9 (1.2)	11.9 (1.4)	12.3 (1.4)
Weight, mean (SD), kg	45.6 (10.9)	52.2 (12.8)	43.9 (11.0)	47.8 (12.3)
BMI	19.1 (3.0)	21.0 (4.4)	18.8 (3.1)	19.8 (3.8)
Ethnicity, n (%)				
Caucasian	49 (76.6)	104 (94.5)	86 (98.9)	239 (91.6)
Other	15 (23.4)	6 (5.5)	1 (1.1)	22 (8.4)
Sexual History				
Postmenarchal, n (%)	21 (32.8)	60 (54.5)	37 (42.5)	118 (45.2)
Sexually active, n (%)	0	0	0	0
Baseline HPV Results Seropositivity, n (%)				
HPV-16	0	0	1 (1.1)	1 (0.4)
HPV-18	0	0	0	0
HPV-6	0	0	2 (2.3)	2 (0.8)
HPV-11	0	1 (0.9)	0	1 (0.4)
<b>Group 3</b>	<b>102</b>	<b>103</b>	<b>105</b>	<b>310</b>
Age, mean (SD), yrs	19.1 (2.7)	18.9 (2.9)	19.9 (2.6)	19.3 (2.8)
Weight, mean (SD), kg	62.9 (9.1)	62.5 (14.8)	61.6 (11.6)	62.3 (12.1)
BMI	22.8 (2.8)	23.3 (4.5)	22.6 (4.0)	22.9 (3.8)
Ethnicity, n (%)				
Caucasian	82 (80.4)	93 (90.3)	101 (96.2)	276 (89.0)
Other	20 (19.6)	10 (9.7)	4 (3.8)	34 (11.0)
Sexual History				
Postmenarchal, n (%)	97 (100)	98 (100)	102 (100)	297 (100)
Sexually active, n (%)	59 (57.8)	65 (63.1)	80 (76.2)	204 (65.8)

Baseline HPV Results Seropositivity, n (%)				
HPV-16	3 (2.9)	2 (1.9)	7 (6.7)	12 (3.9)
HPV-18	2 (2.0)	2 (1.9)	3 (2.9)	7 (2.3)
HPV-6	6 (5.9)	6 (5.8)	2 (1.9)	14 (4.5)
HPV-11	2 (2.0)	1 (1.0)	0	3 (1.0)

**eTable 2. Summary of month 7 anti HPV cLIA geometric mean titres in milli Merck Unit per mL (mMU/mL) of the imputed ITT population of two-dose and three-dose vaccine recipients**

Assay (cLIA)	Girls 9-13 years 2-dose recipients		Girls 9-13 years 3-dose recipients		Women 16-26 years 3-dose recipients		GMT ratio (95% CI)		
	N <sup>1</sup>	GMT (95% CI)	N <sup>1</sup>	GMT (95% CI)	N <sup>1</sup>	GMT (95% CI)	Girls (2-dose)/ Women (3- dose)	Girls (2-dose)/ Girls (3-dose)	Girls (3-dose)/ Women (3-dose)
	<b>7 month data</b>								
Anti-HPV 16		7328		7759		3527	2.08*	0.94	2.20
	259	(6290, 8538)	261	(6668, 9028)	310	(3071, 4050)	(1.62, 2.66)	(0.73, 1.22)	(1.72, 2.81)
Anti-HPV 18		1155		1732		660	1.75*	0.67	2.62
	259	(1009, 1321)	261	(1515, 1981)	310	(583, 747)	(1.41, 2.18)	(0.53, 0.84)	(2.11, 3.27)
Anti-HPV 6		2118		1890		938	2.26	1.12	2.01
	259	(1786, 2513)	261	(1597, 2236)	310	(804, 1096)	(1.72, 2.99)	(0.85, 1.49)	(1.53, 2.65)
Anti-HPV 11		2334		2115		1263	1.85	1.10	1.67
	259	(2085, 2612)	261	(1891, 2366)	310	(1138, 1403)	(1.54, 2.22)	(0.91, 1.33)	(1.39, 2.01)